Cadrenal Therapeutics, Inc. Common Stock Total Assets
Cadrenal Therapeutics, Inc. Common Stock total assets. Based on the latest financial reports, Cadrenal Therapeutics, Inc. Common Stock (CVKD) holds total assets worth $2.86 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CVKD company net worth for the company's overall valuation and market capitalisation.
Total Assets of Cadrenal Therapeutics, Inc. Common Stock (2022–2025)
Total assets of Cadrenal Therapeutics, Inc. Common Stock from 2022 to 2025. This chart illustrates how Cadrenal Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See Cadrenal Therapeutics, Inc. Common Stock stock quote for real-time trading data and today's change.
Cadrenal Therapeutics, Inc. Common Stock - Asset Composition Analysis
Cadrenal Therapeutics, Inc. Common Stock Total Assets Breakdown (December 2025)
Cadrenal Therapeutics, Inc. Common Stock total assets breakdown as of December 2025. Cadrenal Therapeutics, Inc. Common Stock's total assets of $2.86 Million consist of 99.8% current assets and 0.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 92.6% |
| Accounts Receivable | $5.10K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Cadrenal Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Cadrenal Therapeutics, Inc. Common Stock to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cadrenal Therapeutics, Inc. Common Stock's current assets represent 99.8% of total assets in 2025, an increase from 93.5% in 2022.
- Cash Position: Cash and equivalents constituted 92.6% of total assets in 2025, up from 4.2% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Cadrenal Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Cadrenal Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $752.18 Million |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
Cadrenal Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.68 | 4.32 | 0.71 |
| Quick Ratio | 2.68 | 4.32 | 0.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.79 Million | $6.10 Million | $-98.56K |
Cadrenal Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Cadrenal Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.43 |
| Latest Market Cap to Assets Ratio | 2.99 |
| Asset Growth Rate (YoY) | -57.3% |
| Total Assets | $4.33 Million |
| Market Capitalization | $12.93 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cadrenal Therapeutics, Inc. Common Stock's assets at a significant premium (2.99x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Cadrenal Therapeutics, Inc. Common Stock's assets decreased by 57.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cadrenal Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total assets of Cadrenal Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $4.33 Million | -57.26% |
| 2024-12-31 | $10.12 Million | +18.83% |
| 2023-12-31 | $8.52 Million | +994.77% |
| 2022-12-31 | $778.17K | -- |
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with… Read more